Earnings call transcript: ABG Sundal Collier posts strong Q2 2026 revenue growth

ABG Sundal Collier reported Q2 revenue of NOK 727 million (+27% y/y) and expanded adjusted operating margin to 28% (reported 25%), with EPS of NOK 0.24. Debt capital markets volumes reached near all-time highs and equity capital markets improved on stronger IPO sentiment, driving Corporate Financing as the main growth engine. The stock rose 1.11% to $7.30 pre-market, though investors weighed acquisition-integration costs from FIH Partners and the upcoming CEO transition (effective Sept. 1) alongside limited forward quantitative guidance.

Analysis

ABG’s upside is not the quarter itself; it’s that the franchise is showing leverage into a still-open Nordic capital-markets window. When ECM/DCM volumes are healthy, a mid-sized advisory platform with relatively fixed support costs can expand margins faster than revenue, and that usually translates into a higher forward multiple before the street fully extrapolates earnings. The market is likely underweighting how much of the current run-rate can persist if issuance stays constructive into year-end.

The second-order winner set is broader than ABG. If Nordic IPO and DCM activity remains elevated, the real beneficiaries are the exchanges, legal/advisory ecosystem, and competitors with similar advisory mixes, but ABG may be taking share in Denmark after the FIH transaction, which can pressure smaller local boutiques and raise the bar for peers like Pareto/Carnegie-style platforms on distribution and execution. The main loser is any broker-advisory name still carrying a more cost-heavy model with less private-banking diversification, because incremental deal flow now accrues to firms that can cross-sell financing and wealth.

The key risk is that this is a cyclical earnings print disguised as a structural story. If VIX re-accelerates, credit spreads widen, or equity markets lose bid over the next 1-3 months, ECM and M&A can fall off quickly; the 6-18 month bull case depends on management actually delivering the efficiency program and integrating FIH without another round of overlap costs. The CEO transition is less about succession drama and more about whether the next leader preserves fee capture and cost discipline when the cycle normalizes.

Contrarian view: the market may be over-focusing on the leadership change and underappreciating the embedded operating leverage. But it may also be underestimating how much current profitability depends on a benign issuance backdrop; if deal flow merely normalizes rather than improves, earnings growth can stall despite the better cost base. That makes the setup attractive on pullbacks, not as a chase.

Key Decisions for Investors

• Long ABGSF on weakness over the next 1-4 weeks: use any post-earnings drift lower to build a position for a 3-6 month catalyst path into continued DCM/ECM activity and margin normalization; base case is mid-teens upside if volumes stay firm.
• Set a hard risk stop if Nordic equity volatility re-rates higher or credit spreads widen materially over the next quarter; the thesis is most sensitive to a renewed funding-market freeze, not the CEO transition.
• Use ABGSF as a cyclical-financials beta trade rather than a quality compounder: pair long ABGSF against a more rate-sensitive broker/advisory peer with weaker operating leverage if liquidity allows; the relative spread should widen if issuance remains healthy.
• Watch for confirmation in the next 1-2 quarters: if reported margins fail to improve after FIH-related overlap costs roll off, treat the story as range-bound and take profits; if adjusted margins keep expanding, re-rate potential increases materially.
• If seeking lower-risk exposure, prefer a staged entry over options; the name’s liquidity and event risk make short-dated calls less attractive than buying equity after a pullback and reassessing after the next issuance cycle.